MeiraGTx Holdings plc (MGTX) shareholders
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sanofi | 12,197,737 | 15.80% | 13G (passive) amendment | Aug 12, 2024 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (12.60%), Perceptive Life Sciences Master Fund, Ltd. (12.60%) | 11,742,117 | 12.60% | 13D (active) amendment | Apr 17, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (12.90%), Joseph Edelman (12.90%) | 10,441,562 | 12.90% | 13D (active) amendment | Dec 31, 2025 |
| David Rosen Joint filing with Rubric Capital Management LP (9.83%) | 9,100,000 | 9.83% | 13G (passive) amendment | Jun 30, 2026 |
| VOLUNTARY) Johnson & Johnson Innovation-JJDC, Inc. Joint filing with VOLUNTARY) Johnson & Johnson (8.60%) | 6,641,064 | 8.60% | 13G (passive) amendment | Sep 30, 2024 |
| Rubric Capital Management LP Joint filing with David Rosen (7.90%) | 6,175,331 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Adage Capital Partners, L.P. Joint filing with Adage Capital Partners GP, L.L.C. (8.32%), Adage Capital Management, L.P. (8.32%) and 2 more | 5,291,618 | 8.32% | 13G (passive) amendment | Dec 31, 2023 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (5.20%), Robert Atchinson (5.20%) | 4,184,578 | 5.20% | 13G (passive) amendment | Sep 30, 2025 |
| Adena Estate Inc. | 3,266,806 | 5.10% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MGTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sanofi | 12,197,737 | 12.70% | $164.79M | – | 30.86% |
| Perceptive Advisors LLC | 10,786,658 | 11.23% | $145.73M | +460,555 | 2.19% |
| Rubric Capital Management LP | 9,100,000 | 9.47% | $122.94M | +2,100,000 | 1.13% |
| Johnson & Johnson | 6,641,064 | 6.91% | $89.72M | – | 11.23% |
| BlackRock, Inc. | 4,757,178 | 4.95% | $64.27M | +1,589,030 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 4,400,000 | 4.58% | $59.44M | +400,000 | 0.08% |
| Opaleye Management Inc. | 3,550,000 | 3.70% | $47.96M | +1,426,741 | 4.34% |
| Millennium Management LLC | 2,971,752 | 3.09% | $40.15M | −493,947 | 0.01% |
| 683 Capital Management, LLC | 2,300,000 | 2.39% | $31.07M | −150,000 | 1.53% |
| Woodline Partners LP | 1,500,135 | 1.56% | $20.27M | +1,199,812 | 0.06% |
| State Street Corp | 1,393,222 | 1.45% | $18.82M | +639,844 | 0.00% |
| Morgan Stanley | 1,312,703 | 1.37% | $17.73M | −277,237 | 0.00% |
| Knoll Capital Management, LLC | 1,250,000 | 1.30% | $16.89M | – | 9.42% |
| Kennedy Capital Management LLC | 1,105,421 | 1.15% | $14.93M | +247,042 | 0.26% |
| Long Focus Capital Management, LLC | 1,080,300 | 1.12% | $14.59M | +555,555 | 0.37% |
| Jacobs Levy Equity Management, Inc | 1,015,106 | 1.06% | $13.71M | +1,001,433 | 0.05% |
| D. E. Shaw & Co., Inc. | 852,902 | 0.89% | $11.52M | +427,621 | 0.01% |
| Heights Capital Management, Inc | 850,000 | 0.89% | $11.48M | New | 2.65% |
| Geode Capital Management, LLC | 849,082 | 0.88% | $11.47M | +264,183 | 0.00% |
| Vanguard Portfolio Management LLC | 723,563 | 0.75% | $9.78M | +326,282 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 157 | 79M | 82.5% | 39 / 81 | 22 / 12 | 17M | 5M |
| Q1 2026 | 133 | 67M | 70.2% | 20 / 48 | 40 / 15 | 6M | 3M |
| Q4 2025 | 130 | 65M | 67.9% | 20 / 44 | 34 / 12 | 7M | 6M |
| Q3 2025 | 123 | 64M | 66.8% | 24 / 29 | 39 / 13 | 4M | 4M |
| Q2 2025 | 112 | 65M | 67.2% | 17 / 36 | 39 / 22 | 8M | 3M |
| Q1 2025 | 118 | 60M | 62.5% | 22 / 44 | 33 / 5 | 5M | 3M |
| Q4 2024 | 102 | 58M | 60.5% | 17 / 45 | 22 / 14 | 15M | 3M |
| Q3 2024 | 99 | 46M | 47.4% | 11 / 37 | 30 / 6 | 8M | 1M |
| Q2 2024 | 95 | 41M | 42.5% | 13 / 38 | 29 / 14 | 2M | 1M |
| Q1 2024 | 96 | 40M | 41.5% | 19 / 29 | 30 / 8 | 1M | 1M |
| Q4 2023 | 86 | 40M | 41.3% | 17 / 31 | 24 / 5 | 3M | 1M |
| Q3 2023 | 75 | 38M | 39.3% | 7 / 20 | 23 / 11 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
42 funds held MGTX in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MGTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Nuveen Quant Small Cap Equity Fund | 526,570 | 0.55% | $6.21M | 0.15% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 232,099 | 0.24% | $2.47M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 133,062 | 0.14% | $1.42M | 0.01% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 113,461 | 0.12% | $1.53M | 0.05% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 79,737 | 0.08% | $940.10K | 0.02% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 77,592 | 0.08% | $914.81K | 0.00% | Jul 31, 2026 |
| Nuveen Quant Mid Cap Growth Fund | 71,980 | 0.07% | $848.64K | 0.13% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 57,010 | 0.06% | $672.15K | 0.02% | Jul 31, 2026 |
| AlphaCentric Life Sciences and Healthcare Fund | 54,469 | 0.06% | $735.88K | 1.58% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 52,420 | 0.05% | $708.19K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 31,787 | 0.03% | $338.53K | 0.02% | May 31, 2026 |
| Small Cap Index Fund | 30,333 | 0.03% | $409.80K | 0.02% | Jun 30, 2026 |
| Small Company Growth Portfolio | 29,450 | 0.03% | $397.87K | 0.02% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 28,718 | 0.03% | $338.59K | 0.02% | Jul 31, 2026 |
| Small Cap Equity Fund | 24,200 | 0.03% | $326.94K | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alexandria Forbes | PRESIDENT & CEO, Director | 1,268,580 | 1.32% | Nov 17, 2026 |
| Richard Giroux | CFO & COO | 942,682 | 0.98% | Oct 20, 2026 |
| Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | 613,187 | 0.64% | Oct 6, 2026 |
| Robert K. Zeldin | CHIEF MEDICAL OFFICER | 146,204 | 0.15% | Jun 29, 2026 |
| Robert J. Wollin | GENERAL COUNSEL AND SECRETARY | 63,326 | 0.07% | Jun 29, 2026 |
| Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | – | – | May 14, 2026 |
| Alan Sebulsky | Director | 34,500 | 0.04% | Sep 24, 2026 |
| Nicole Seligman | Director | 5,000 | 0.01% | Jun 15, 2026 |
| Debra Yu | Director | – | – | Jun 15, 2026 |
| Ellen Hukkelhoven | Director | 0 | – | Jun 15, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director, 10% owner | 10,786,658 | 11.23% | Jun 15, 2026 |
| Joseph Edelman | Director, 10% owner | 12,531,103 | 13.05% | Jun 15, 2026 |
| Thomas E. Shenk | Director | 157,476 | 0.16% | Jun 15, 2026 |
| Advisors Llc Perceptive | Director, 10% owner | 6,933,277 | 7.22% | Jun 15, 2026 |
| Keith R. Harris | Director | 200,000 | 0.21% | Jun 15, 2026 |
| Neil Mendoza | Director | 12,883 | 0.01% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexandria Forbes PRESIDENT & CEO, Director | Nov 17, 2026 | Sale(10b5-1 plan) | −62,000 | $8.45 | $523.90K | 1,239,595 |
| Alexandria Forbes PRESIDENT & CEO, Director | Nov 17, 2026 | Gift | −24,100 | – | – | 1,301,595 |
| Richard Giroux CFO & COO | Oct 20, 2026 | Sale(10b5-1 plan) | −56,000 | $9.95 | $557.20K | 852,530 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY | Oct 6, 2026 | Sale(10b5-1 plan) | −27,659 | $10.64 | $294.29K | 613,187 |
| Alexandria Forbes PRESIDENT & CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −62,000 | $13.86 | $859.32K | 1,325,695 |
| Richard Giroux CFO & COO | Jul 21, 2026 | Sale(10b5-1 plan) | −56,000 | $12.51 | $700.56K | 908,530 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 7, 2026 | Sale(10b5-1 plan) | −2,547 | $13.86 | $35.30K | 665,958 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 7, 2026 | Sale(10b5-1 plan) | −25,112 | $14.90 | $374.17K | 640,846 |
| Keith R. Harris Director | Jun 10, 2026 | Option exercise | +75,000 | – | – | 200,000 |
| Richard Giroux CFO & COO | May 27, 2026 | Gift | −7,000 | – | – | 964,530 |
| Alexandria Forbes PRESIDENT & CEO, Director | May 19, 2026 | Sale(10b5-1 plan) | −62,000 | $9.17 | $568.54K | 1,387,695 |
| Richard Giroux CFO & COO | Apr 21, 2026 | Sale(10b5-1 plan) | −56,000 | $10.22 | $572.32K | 971,530 |
| Life Sciences Master Fund Ltd Perceptive Director, 10% owner | Apr 17, 2026 | Award | +555,555 | $9.00 | $5.00M | 10,786,658 |
| Stuart Naylor CHIEF DEV. OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −27,661 | $9.36 | $258.91K | 668,505 |
| Alexandria Forbes PRESIDENT & CEO, Director | Mar 24, 2026 | Sale(10b5-1 plan) | −62,000 | $7.41 | $459.42K | 1,449,695 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2026 | Tax withholding | −2,952 | $7.45 | $21.99K | 172,888 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2026 | Option exercise | +7,500 | – | – | 175,840 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2026 | Option exercise | +11,250 | – | – | 63,326 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2026 | Tax withholding | −5,949 | $7.45 | $44.32K | 57,377 |
| Richard Giroux CFO & COO | Feb 21, 2026 | Option exercise | +60,000 | – | – | 1,059,256 |
| Richard Giroux CFO & COO | Feb 21, 2026 | Tax withholding | −31,726 | $7.45 | $236.36K | 1,027,530 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2026 | Option exercise | +25,000 | – | – | 707,916 |
| Stuart Naylor CHIEF DEV. OFFICER | Feb 21, 2026 | Tax withholding | −11,750 | $7.45 | $87.54K | 696,166 |
| Alexandria Forbes PRESIDENT & CEO, Director | Feb 21, 2026 | Option exercise | +62,500 | – | – | 1,544,743 |
| Alexandria Forbes PRESIDENT & CEO, Director | Feb 21, 2026 | Tax withholding | −33,048 | $7.45 | $246.21K | 1,511,695 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 17, 2026 | Tax withholding | −27,206 | $7.42 | $201.87K | 52,076 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 17, 2026 | Option exercise | +50,000 | – | – | 79,282 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 17, 2026 | Tax withholding | −35,250 | $7.42 | $261.56K | 682,916 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 17, 2026 | Option exercise | +75,000 | – | – | 718,166 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 17, 2026 | Tax withholding | −13,951 | $7.42 | $103.52K | 168,340 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 17, 2026 | Option exercise | +35,000 | – | – | 182,291 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 17, 2026 | Tax withholding | −163,916 | $7.42 | $1.22M | 1,482,243 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 17, 2026 | Option exercise | +310,000 | – | – | 1,646,159 |
| Richard Giroux CFO & COO | Jan 17, 2026 | Tax withholding | −163,916 | $7.42 | $1.22M | 999,256 |
| Richard Giroux CFO & COO | Jan 17, 2026 | Option exercise | +310,000 | – | – | 1,163,172 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Tax withholding | −7,814 | $7.73 | $60.40K | 146,204 |
| Richard Giroux CFO & COO | Jan 7, 2026 | Option exercise | +52,500 | – | – | 881,994 |
| Richard Giroux CFO & COO | Jan 7, 2026 | Tax withholding | −28,822 | $7.73 | $222.79K | 853,172 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 7, 2026 | Option exercise | +7,500 | – | – | 33,646 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Jan 7, 2026 | Tax withholding | −4,364 | $7.73 | $33.73K | 29,282 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 7, 2026 | Option exercise | +37,500 | – | – | 660,791 |
| Stuart Naylor CHIEF DEV. OFFICER | Jan 7, 2026 | Tax withholding | −17,625 | $7.73 | $136.24K | 643,166 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 7, 2026 | Tax withholding | −34,074 | $7.73 | $263.39K | 1,336,159 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jan 7, 2026 | Option exercise | +62,500 | – | – | 1,370,233 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Option exercise | +17,500 | – | – | 154,020 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Jan 7, 2026 | Tax withholding | −6,729 | $7.73 | $52.02K | 147,291 |
| Life Sciences Master Fund Ltd Perceptive Director, 10% owner | Dec 31, 2025 | Returned to company | −2,300,000 | $7.91 | $18.19M | 10,231,103 |
| Alexandria Forbes PRESIDENT & CEO, Director | Dec 23, 2025 | Gift | −6,250 | – | – | 1,307,733 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Nov 20, 2025 | Gift | −5,000 | – | – | 26,146 |
| Richard Giroux CFO & COO | Oct 21, 2025 | Sale(10b5-1 plan) | −24,000 | $8.87 | $212.88K | 829,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Oct 7, 2025 | Sale(10b5-1 plan) | −47,500 | $8.39 | $398.53K | 1,313,983 |
| Richard Giroux CFO & COO | Jul 22, 2025 | Sale(10b5-1 plan) | −24,000 | $8.52 | $204.48K | 853,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Jul 8, 2025 | Sale(10b5-1 plan) | −47,500 | $7.97 | $378.58K | 1,361,483 |
| Richard Giroux CFO & COO | Jun 30, 2025 | Gift | −5,000 | – | – | 877,494 |
| Keith R. Harris Director | Jun 6, 2025 | Option exercise | +75,000 | – | – | 125,000 |
| Richard Giroux CFO & COO | Apr 22, 2025 | Sale(10b5-1 plan) | −24,000 | $6.00 | $144.00K | 882,494 |
| Alexandria Forbes PRESIDENT & CEO, Director | Apr 8, 2025 | Sale(10b5-1 plan) | −47,500 | $5.34 | $253.65K | 1,408,983 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2025 | Tax withholding | −12,116 | $7.30 | $88.45K | 31,146 |
| Robert J. Wollin GENERAL COUNSEL AND SECRETARY | Feb 21, 2025 | Option exercise | +22,500 | – | – | 43,262 |
| Robert K. Zeldin CHIEF MEDICAL OFFICER | Feb 21, 2025 | Tax withholding | −5,903 | $7.30 | $43.09K | 136,520 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MeiraGTx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,962 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Giroux Officer | Oct 20, 2026 | 56,000 | $557.20K | Oct 20, 2026 | Incentive Compensation Stock Grant |
| Stuart Naylor Officer | Oct 6, 2026 | 27,659 | $294.32K | Oct 6, 2026 | Restricted Stock Vesting |
| Alexandria Forbes Officer, Director | Aug 18, 2026 | 62,000 | $859.32K | Aug 18, 2026 | Incentive Compensation Stock Grant |
| Richard Giroux Officer | Jul 21, 2026 | 56,000 | $700.56K | Jul 21, 2026 | Incentive Compensation Stock Grant |
| Stuart Naylor Officer | Jul 7, 2026 | 27,659 | $368.69K | Jul 7, 2026 | Restricted Stock Vesting |
| Alexandria Forbes Officer, Director | May 19, 2026 | 62,000 | $568.54K | May 19, 2026 | Incentive Compensation Stock Grant |
| Richard Giroux Officer | Apr 21, 2026 | 56,000 | $572.55K | Apr 21, 2026 | Incentive Compensation Stock Grant |
| Stuart Naylor Officer | Apr 7, 2026 | 27,661 | $258.87K | Apr 7, 2026 | Restricted Stock Vesting |
| Alexandria Forbes Officer, Director | Mar 24, 2026 | 62,000 | $459.42K | Mar 24, 2026 | Incentive Compensation Stock Grant |
| Richard Giroux Officer | Oct 21, 2025 | 24,000 | $212.88K | Oct 21, 2025 | Stock Bonus |
| Alexandria Forbes Officer, Director | Oct 7, 2025 | 47,500 | $398.53K | Oct 7, 2025 | Incentive Compensation Stock Grant |
| Richard Giroux Officer | Jul 22, 2025 | 24,000 | $204.48K | Jul 22, 2025 | Stock Bonus |
| Alexandria Forbes Officer, Director | Jul 8, 2025 | 47,500 | $378.58K | Jul 8, 2025 | Incentive Compensation Stock Grant |
| Richard Giroux Officer | Apr 22, 2025 | 24,000 | $144.00K | Apr 22, 2025 | Stock Bonus |
| Alexandria Forbes President / CEO | Apr 8, 2025 | 47,500 | $251.27K | Apr 8, 2025 | Stock Bonus |
See a number that looks wrong?